The "cost" of treating to target: cross-sectional analysis of patients with poorly controlled type 2 diabetes in Australian general practice

John Furler, Justin W S Hii, Danny Liew, Irene Blackberry, James Best, Leonie Segal, Doris Young, John Furler, Justin W S Hii, Danny Liew, Irene Blackberry, James Best, Leonie Segal, Doris Young

Abstract

Background: To describe the current treatment gap in management of cardiovascular risk factors in patients with poorly controlled type 2 diabetes in general practice as well as the associated financial and therapeutic burden of pharmacological treatment.

Methods: Cross-sectional analysis of data from the Patient Engagement and Coaching for Health trial. This totalled 473 patients from 59 general practices with participants eligible if they had HbA1c > 7.5%. Main outcome measures included proportions of patients not within target risk factor levels and weighted average mean annual cost for cardiometabolic medications and factors associated with costs. Medication costs were derived from the Australian Pharmaceutical Benefits Schedule.

Results: Average age was 63 (range 27-89). Average HbA1c was 8.1% and average duration of diabetes was 10 years. 35% of patients had at least one micro or macrovascular complication and patients were taking a mean of 4 cardio-metabolic medications. The majority of participants on treatment for cardiovascular risk factors were not achieving clinical targets, with 74% and 75% of patients out of target range for blood pressure and lipids respectively. A significant proportion of those not meeting clinical targets were not on treatment at all. The weighted mean annual cost for cardiometabolic medications was AUD$1384.20 per patient (2006-07). Independent factors associated with cost included age, duration of diabetes, history of acute myocardial infarction, proteinuria, increased waist circumference and depression.

Conclusions: Treatment rates for cardiovascular risk factors in patients with type 2 diabetes in our participants are higher than those identified in earlier studies. However, rates of achieving target levels remain low despite the large 'pill burden' and substantial associated fiscal costs to individuals and the community. The complexities of balancing the overall benefits of treatment intensification against potential disadvantages for patients and health care systems in primary care warrants further investigation.

Figures

Figure 1
Figure 1
Flowchart of participant recruitment.
Figure 2
Figure 2
Blood pressure (n = 460).
Figure 3
Figure 3
Lipids (n = 424).

References

    1. Australian Institute of Health and Welfare. Diabetes: Australian facts. Canberra: AIHW2008; 2008.
    1. Dunstan D, Zimmett P, Welborn T. The final report of the Australian diabetes, obesity and lifestyle study (AusDiab) Melbourne: International Diabetes Institute; 2001.
    1. Davis WA, Knuiman MW, Hendrie D, Davis TME. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle diabetes study. Intern Med J. 2006;36(3):155–161. doi: 10.1111/j.1445-5994.2006.01014.x.
    1. National Health Priority Action Council (NHPAC) National chronic disease strategy. Canberra: Australian Government Department of Health and Ageing; 2006.
    1. Norris S, Lau J, Smith S, Schmid C, Engelgau M. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25(7):1159–1171. doi: 10.2337/diacare.25.7.1159.
    1. Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet. 2004;363(9421):1589–1597. doi: 10.1016/S0140-6736(04)16202-8. 2004/5/15.
    1. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(5):580–591.
    1. Bonney MA, Carter S, Burns J, Powell-Davies G, Harris MF. National divisions diabetes program, data collation project, volume 3, divisions of general practice - diabetes profiles. Quality of care and health outcomes - collated division data. Sydney: Centre for GP Integration Studies, School of Community Medicine, University of New South Wales; 2000.
    1. Improvement Foundation. Austalian primary care collaboratives program. 2012. Accessed July 23 2012]; Available from:
    1. Australian Government Department of Human Services. Practice incentives program diabetes incentive guidelines—July 2012. 2012 [25 July 2012] Available from: .
    1. Wan Q, Harris MF, Jayasinghe UW, Flack J, Georgiou A, Penn DL. Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellitus in Australian general practice. Qual Saf Health Care. 2006;15(2):131–135. doi: 10.1136/qshc.2005.014845.
    1. Khunti K, Gadsby R, Millett C, Majeed A, Davies M. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the quality and outcomes framework for diabetes. Diabet Med. 2007;24(12):1436–1441. doi: 10.1111/j.1464-5491.2007.02276.x.
    1. Crosson JC, Ohman-Strickland PA, Campbell S, Phillips RL, Roland MO, Kontopantelis E. A comparison of chronic illness care quality in US and UK family medicine practices prior to pay-for-performance initiatives. Fam Pract. 2009;26(6):510–516. doi: 10.1093/fampra/cmp056.
    1. Young D, Furler J, Vale M, Walker C, Segal L, Dunning P. Patient engagement and coaching for health: the PEACH study - a cluster randomised controlled trial using the telephone to coach people with type 2 diabetes to engage with their GPs to improve diabetes care: a study protocol. BMC Fam Pract. 2007. 8(20).
    1. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem. 1987;33(12):2267–2271.
    1. Harris P, Mann L, Phillips P, Snowdon T, Webster C. Diabetes management in general practice: 12th edition. Melbourne: Diabetes Australia and the Royal Australian College of General Practitioners; 2005.
    1. Ademi Z, Liew D, Chew D, Conner G, Shiel L, Nelson M. Drug treatment and cost of cardiovascular disease in Australia. Cardiovasc Ther. 2009;27:164–172. doi: 10.1111/j.1755-5922.2009.00090.x.
    1. Commonwealth of Australia. Pharmaceutical benefits schedule item reports. Period September 2006 to September 2007. Accessed 11 May 2012; Available from: .
    1. Brunner EJ, Marmot M. In: Social determinants of health. 2. Marmot MG, Wilkinson RG, editor. Oxford; New York: Oxford University Press; 2006. Social organisation, stress and health; pp. 6–30.
    1. Rossi S, editor. Australian Medicines Handbook 2013. Adelaide: Australian Medicines Handbook Pty Ltd; 2013.
    1. Expert Group Psychotropic. Therapeutic guidelines (Psychotropics) Melbourne: Therapeutic Guidelines Limited; 2008.
    1. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Position statement on lipid management. Heart Lung Circ. 2005;14(4):275–291.
    1. Thomas MC, Nestel PJ. Management of dyslipidaemia in patients with type 2 diabetes in Australian primary care. Med J Aust. 2007;186(3):128–130.
    1. McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes care. 2002;25(4):718–723. doi: 10.2337/diacare.25.4.718.
    1. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med. 2008;168(19):2088–2094. doi: 10.1001/archinte.168.19.2088. 2008.
    1. The Health and Social Care Information Centre PaPCS. Prescribing for Diabetes in England: 2005/6 to 2011/12. London: NHS Information Centre; 2012.
    1. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes care. 2003;26(5):1408–1412. doi: 10.2337/diacare.26.5.1408. 2003.
    1. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28(3):600–606. doi: 10.2337/diacare.28.3.600. 2005.
    1. Webbie K, O’Brien K, AIHW. Use of medicines by Australians with diabetes. Canberra: AIHW; 2006.
    1. Parchman ML, Pugh JA, Romero RL, Bowers KW. Competing demands or clinical inertia: the case of elevated Glycosylated hemoglobin. Ann Fam Med. 2007;5(3):196–201. doi: 10.1370/afm.679. 2007.
    1. Wolpert HA, Anderson BJ. Management of diabetes: are doctors framing the benefits from the wrong perspective? BMJ. 2001;323(7319):994–996. 2001.
    1. Vale M, Sundararajan V, Best J, Jelinek M. Four year follow-up of the multicentre RCT of the COACH study shows that the COACH Programme keeps patients out of hospital. Eur Heart J. 2005;26:501–502.
    1. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. Br Med J. 2011;343:d7995. doi: 10.1136/bmj.d7995.
    1. Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia. 2010;53(10):2079–2085. doi: 10.1007/s00125-010-1864-z.
    1. Dowrick C. Beyond depression: a new approach to understanding and management. 2. Oxford: Oxford University Press; 2009.
    1. Guthrie B, Inkster M, Fahey T. Tackling therapeutic inertia: role of treatment data in quality indicators. BMJ (Clinical research ed) 2007;335(7619):542–544. doi: 10.1136/. 2007.
    1. May C, Montori VM, Mair FS. We need minimally disruptive medicine. Br Med J. 2009;339:b2803. doi: 10.1136/bmj.b2803.
    1. Valderas JM, Alonso J. Patient reported outcome measures: a model-based classification system for research and clinical practice. Qual Life Res. 2008;17(9):1125–1135. doi: 10.1007/s11136-008-9396-4.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa